Diclofenac

Evidence Level: L5 Predicted Indications: 10

Table of Contents

  1. Diclofenac
    1. Pharmacist Assessment Report
    2. Diclofenac: From Actinic Keratosis and Inflammatory Arthritis to Hypotrichosis Simplex of the Scalp
    3. One-Sentence Summary
    4. Quick Overview
    5. Why is This Prediction Reasonable?
    6. Clinical Trial Evidence
    7. Literature Evidence
    8. Canada Market Information
    9. Safety Considerations
    10. Conclusion and Next Steps
    11. Disclaimer

Pharmacist Assessment Report

Diclofenac: From Actinic Keratosis and Inflammatory Arthritis to Hypotrichosis Simplex of the Scalp

One-Sentence Summary

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) used for actinic keratosis and for painful inflammatory joint conditions such as rheumatoid arthritis and osteoarthritis. The TxGNN model predicts it may be useful for hypotrichosis simplex of the scalp, a rare genetic hair-loss disorder, but there are 0 clinical trials and 0 publications supporting this prediction. It rests on a computational prediction alone.

Quick Overview

Item Content
Original Indication Actinic keratosis; rheumatoid arthritis; osteoarthritis; ankylosing spondylitis (Health Canada indication text was not available)
Predicted New Indication Hypotrichosis simplex of the scalp
TxGNN Prediction Score 0.9969
Evidence Level L5
Canada Market Status Marketed (marketed DINs on record: at least 18; cancelled: 2)
Number of DINs at least 20
Recommended Decision Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, diclofenac is an NSAID that reduces prostaglandin-driven inflammation and pain. Its efficacy in inflammatory joint disease and actinic keratosis is established, but it is not mechanistically expected to apply to hypotrichosis simplex of the scalp.

Hypotrichosis simplex of the scalp is a rare inherited disorder of the hair follicle. A structural or genetic defect of this kind is not expected to respond to an anti-inflammatory drug, and no plausible link to diclofenac’s mechanism has been identified. The very high score (0.9969) most likely reflects closeness between terms in the model’s network rather than a biological rationale. Treat this prediction as a computational signal only, not as evidence of efficacy.

A better-supported candidate appears further down the prediction list: juvenile idiopathic arthritis (see the Conclusion).

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

Dosage form and approved indication text were not available for these products. Five main authorizations are listed below.

DIN Product Name
00632724 VOLTAREN
02338580 VOLTAREN EMULGEL JOINT PAIN REGULAR STRENGTH
02247265 PENNSAID
02381680 CAMBIA
01940414 VOLTAREN OPHTHA

The product names suggest oral, topical gel and ophthalmic formulations are all on the market.

Safety Considerations

  • Disease-level cautions (conditions in which diclofenac is flagged as contraindicated or to be avoided; these are not label text):
    • Cardiovascular: hypertension, congestive heart failure, myocardial infarction, stroke and cerebrovascular disorders, other heart disease
    • Gastrointestinal and hepatic: peptic ulcer disease (including active), inflammatory bowel disease, liver disease or failure, drug-induced liver injury, gallbladder disease
    • Respiratory: asthma, including allergic and intrinsic forms
    • Blood: blood coagulation disease, anaemia (including macrocytic), haemoglobinopathy
    • Metabolic and other: diabetes mellitus, diabetic ketoacidosis, substance abuse or dependence, keratitis
  • Drug Interactions: The interaction screen returned 100 interacting drugs in total. The 20 reviewed here included mostly Moderate and some Minor interactions.
    • Moderate: corticosteroids (hydrocortisone, dexamethasone, betamethasone, budesonide, triamcinolone), acetylsalicylic acid, mesalazine, balsalazide, metformin, sulfonylureas (glimepiride, glipizide, chlorpropamide, acetohexamide), exenatide, aprepitant, fenfluramine, dexfenfluramine
    • Minor: H2 blockers (famotidine, ranitidine, cimetidine)

Please refer to the package insert for official warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction for hypotrichosis simplex of the scalp has no trial or literature support, no plausible mechanistic link, and an L5 evidence level. The drug’s safety profile also includes cardiovascular, gastrointestinal, hepatic and renal cautions that would need strong evidence of benefit to justify. Among the other predictions, juvenile idiopathic arthritis (L3, score 0.9925) has small, dated studies of diclofenac, but these only suggest symptomatic benefit. NSAIDs are already a standard adjunct in that condition, so it is an established use rather than new repurposing.

To proceed, the following is needed:

  • Mechanistic or preclinical data showing a plausible role for COX inhibition in the hair follicle disorder, if this indication is to be pursued
  • Detailed mechanism of action data (MOA)
  • Health Canada package insert warnings and contraindications, plus dosage form and indication text for each DIN
  • For juvenile idiopathic arthritis: a structured review of the paediatric diclofenac studies to confirm the benefit and the paediatric safety profile

    Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

This site uses Just the Docs, a documentation theme for Jekyll.